Nuclear factor-Ä̧B plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells

Scientific Reports

Volumn 4, Issue , 2014, Pages 1-8

  Oida, Kumiko ^a,b   Matsuda, Akira ^a   Jung, Kyungsook ^a   Xia, Yan ^a   Jang, Hyosun ^a   Amagai, Yosuke ^a   Ahn, Ginnae ^a   Nishikawa, Sho ^a   Ishizaka, Saori ^a   Jensen Jarolim, Erika ^b,c   Matsuda, Hiroshi ^a   Tanaka, Akane ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BENZAMIDE DERIVATIVE; ESTROGEN RECEPTOR; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-5-CHLORO-2-HYDROXYBENZAMIDE; SMALL INTERFERING RNA; TAMOXIFEN;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 9; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; RECEPTORS, ESTROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 84894562598     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04057     Document Type: Article

References (41)

1. Harvey, J. M., Clark, G. M., Osborne, C. K. & Allred, D. C. Estrogen receptor status by endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474-1481 (1999).
2. Jensen, E. V. On the mechanism of estrogen action. Perspect. Biol. Med. 6, 47-54 (1962).
3. Kuiper, G. G. et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93, 5925-5930 (1996). (Pubitemid 26190778)
4. Hamis, L. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007).
5. Hammond, M. E. et al. American Society of Clinical Oncology/College of American pathogenesis guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784-2795 (2010).
6. Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007). (Pubitemid 350003059)
7. Cole, M. P., Jones, C. T. & Todd, I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br. J. Cancer 25, 270-275 (1971).
8. Fawell, S. E. et al. Inhibition of estrogen receptor-DNA binding by the ''pure'' anti-estrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA 87, 6883-6888 (1990).
9. Hoskins, J. M., Carey, L. A. & McLeod, H. L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature Rev. Cancer 9, 576-586 (2009).
10. Jensen, E. V. & Jordan, V. C. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9, 1980-1989 (2003). (Pubitemid 36687616)
11. Riggs, B. L. & Hartmann, L. C. Selective estrogen-receptor modulators2Mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618-629 (2003). (Pubitemid 36210865)
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365, 1687-1717 (2005).
13. Cancer Incidence, Mortality and Prevalence Worldwide in 2008, http://globocan. iarc.fr, International Agency for Research on Cancer, World Health Organization.
14. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nature Rev. Cancer 9, 631-643 (2009).
15. Rhodes, L. V. et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 71, 603-613 (2011).
16. van Agthoven, T. et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J. Clin. Oncol. 27, 542-549 (2009).
17. Oeckinghaus, A., Hayden, M. S. & Ghosh, S. Crosstalk in NF-kB signaling pathways. Nature Immunol. 12, 695-708 (2011).
18. Pasparakis, M., Luedde, T. & Schmidt-Supprian, M. Dissection of the NF-kB signaling cascade in transgenic and knockout mice. Cell Death Differ. 13, 861-872 (2006).
19. Hayden, M. S. & Ghosh, S. NF-kB in immunobiology. Cell Res. 21, 223-244 (2011).
20. Scheidereit, C. IkB kinase complexes: gateways to NF-kB activation and transcription. Oncogene 25, 6685-6705 (2006). (Pubitemid 44657846)
21. Perkins, N. D. The diverse and complex roles of NF-kB subunits in cancer. Nat. Rev. Cancer 12, 121-132 (2012).
22. Frasor, J. et al. Positive cross-talk between estrogen receptor and NF-kB in breast cancer. Cancer Res. 69, 8918-8925 (2009).
23. Zhou, Y. et al. Activation of nuclear factor-kB (NFkB) identifies a high-risk subset of hormone-dependent breast cancers. Int. J. Biochem. Cell Biol. 37, 1130-1144 (2005). (Pubitemid 40311751)
24. Tanaka, A., Muto, S., Konno, M., Itai, A. & Matsuda, H. A new IkB kinase b inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 66, 419-426 (2006). (Pubitemid 43166050)
25. Heldring, N. et al. Esrogen receptors: How do they signal and what are their targets. Physiol. Rev. 87, 905-931 (2007). (Pubitemid 47084672)
26. Gross, J. & Lapiere, C. M. Collagenolytic activity in amphibian tissue: a tissue culture assay. Proc. Natl. Acad. Sci. USA 48, 1014-1022 (1962).
27. Page-McCaw, A., Ewald, A. J. & Werb, Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nat. Rev. Mol. Cell Biol. 8, 221-233 (2007).
28. Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67 (2010).
29. Egeblad, M. & Werb, Z.New functions for the matrix metalloproteinasesincancer progression. Nat. Rev. Cancer 2, 161-174 (2002). (Pubitemid 37328786)
30. Sternlicht, M. D. & Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516 (2001). (Pubitemid 33096184)
31. Tanaka, A. et al. A novel NF-kB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105, 2324-2331 (2005). (Pubitemid 40387026)
32. Johnston, S. R. D. et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 55, 3331-3338 (1995).
33. Pan, Z. et al. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat. Med. 17, 708-714 (2011).
34. Berthois, Y., Katzenellenbogen, J. A. & Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in cuture. Proc. Natl. Acad. Sci. USA 83, 2496-2500 (1986). (Pubitemid 16026909)
35. Devleeschouwer, N. et al. Growth factor-like activity of phenol red preparations in the MCF-7 breast cancer cell line. Anticancer Res. 12, 789-794 (1992).
36. Chen, Z. et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 9, 1586-1597 (1995).
37. Padera, T. P. et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886 (2002). (Pubitemid 34596277)
38. Barre, B. & Perkins, N. D. A cell cycle regulatory network controlling NF-kB subunit activity and function. EMBO J. 26, 4841-4855 (2007). (Pubitemid 350191299)
39. Polyak, K. et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-b and contact inhibition to cell cycle arrest. Genes Dev. 8, 9-22 (1994).
40. Xiong, X., Zhang, H. & Beach, D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev. 7, 1572-1583 (1993). (Pubitemid 23234350)
41. Clarke, R. et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signalling. Oncogene 22, 7316-7339 (2003). (Pubitemid 37492898)